Overview

A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the absorption, the metabolic pathways and the excretion of ibrutinib in healthy male adult participants after administration of a single oral dose of 50 mg to 140 mg (5 mg/mL solution) of unlabeled ibrutinib admixed with 14C ibrutinib.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC